ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Breast Cancer

Breast Cancer

Maintenance therapy with low-dose cyclophosphamide and methotrexate in women with hormone receptor-negative early breast cancer did not improve disease-free survival.

A 34-year-old, gravida 2, para 1, previously healthy African-American woman presented with a right breast mass on self-examination in the second trimester of pregnancy.

OPT-822/821 vaccination did not show any improvement in progression-free survival as maintenance therapy compared with placebo for metastatic breast cancer. But in those patients who had an immune response, the vaccine did appear to show activity.

Among breast cancer survivors, black women are far less likely to receive BRCA testing and preventive surgery than white or Hispanic women.

Heavily pretreated women with metastatic breast cancer had significant improvements in progression-free survival and overall response rate when treated with the combination of utidelone plus capecitabine compared with capecitabine alone.

Postmenopausal women with early breast cancer benefit from extending AI therapy with letrozole from 5 to 10 years, and show no worsening of quality of life.

Directly engaging and recruiting patients online using social media will allow broader participation in cancer genomics research and hasten clinical advances.

Pages

Subscribe to Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.